Simulations Plus, Inc. filings document a California operating company that reports as a provider of model-informed and AI-accelerated drug development software and services. Its 8-K reports furnish quarterly financial results, investor presentation materials, preliminary operating updates, guidance-related disclosures, and Regulation FD information tied to its software and services business.
The company’s proxy and governance filings cover annual meeting voting, director and executive compensation matters, shareholder approval of amendments to the 2021 Equity Incentive Plan, and common-stock authorization for equity awards. Other material-event reports document executive employment agreements, changes in the independent registered public accounting firm, internal-control and segment-reporting matters, and related audit committee actions.
Simulations Plus (SLP), a provider of cheminformatics and biosimulation solutions for the biopharma industry, announced a rescheduling of its Q3 FY2025 financial results release and conference call. The company has delayed these events from the original date of July 2, 2025, to the following schedule:
- Conference call: July 14, 2025, at 5:00 p.m. Eastern Time
- Financial results release: July 15, 2025, before market open
The delay utilizes the maximum time allowed under regulations following the company's status change from a large accelerated filer to a non-accelerated filer. This material event was reported via Form 8-K and includes a press release (Exhibit 99.1) containing the rescheduling details. The filing indicates a notable change in the company's filing status and timing of financial disclosures, which could be significant for investors tracking reporting obligations and corporate governance.